TD Asset Management Inc Sells 167,546 Shares of Edwards Lifesciences Corporation $EW

TD Asset Management Inc cut its position in Edwards Lifesciences Corporation (NYSE:EW) by 18.4% in the second quarter, HoldingsChannel.com reports. The firm owned 743,640 shares of the medical research company’s stock after selling 167,546 shares during the quarter. TD Asset Management Inc’s holdings in Edwards Lifesciences were worth $58,160,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Quantbot Technologies LP bought a new position in Edwards Lifesciences in the 1st quarter worth $26,000. SouthState Corp purchased a new position in shares of Edwards Lifesciences in the first quarter valued at about $27,000. Rossby Financial LCC bought a new position in shares of Edwards Lifesciences in the first quarter worth about $29,000. Costello Asset Management INC purchased a new stake in shares of Edwards Lifesciences during the first quarter worth about $29,000. Finally, Global X Japan Co. Ltd. raised its stake in Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 216 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on EW shares. Royal Bank Of Canada upped their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Wells Fargo & Company upped their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research report on Thursday, August 7th. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Stifel Nicolaus set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Monday, September 22nd. Finally, Evercore ISI set a $88.00 price objective on shares of Edwards Lifesciences and gave the company an “outperform” rating in a report on Tuesday, October 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $87.06.

Insider Activity

In related news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $72.92 on Thursday. The stock has a market cap of $42.81 billion, a price-to-earnings ratio of 10.49, a price-to-earnings-growth ratio of 3.52 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a 50 day moving average price of $77.72 and a 200-day moving average price of $76.14. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $83.00.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the company earned $0.70 earnings per share. Edwards Lifesciences’s revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.